India markets closed
  • BSE SENSEX

    52,586.84
    -66.26 (-0.13%)
     
  • Nifty 50

    15,763.05
    -15.45 (-0.10%)
     
  • USD/INR

    74.3370
    -0.1630 (-0.22%)
     
  • Dow

    34,935.47
    -149.03 (-0.42%)
     
  • Nasdaq

    14,672.68
    -105.62 (-0.71%)
     
  • BTC-INR

    3,059,650.50
    -12,365.00 (-0.40%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • Hang Seng

    25,961.03
    -354.27 (-1.35%)
     
  • Nikkei

    27,283.59
    -498.81 (-1.80%)
     
  • EUR/INR

    88.3321
    +0.0734 (+0.08%)
     
  • GBP/INR

    103.4671
    -0.1229 (-0.12%)
     
  • AED/INR

    20.1960
    -0.0430 (-0.21%)
     
  • INR/JPY

    1.4721
    -0.0004 (-0.03%)
     
  • SGD/INR

    54.9030
    -0.0380 (-0.07%)
     

ReCode Therapeutics to Participate in Upcoming June Investor Conferences

·1-min read

MENLO PARK, Calif. & DALLAS, Jun 14, 2021--(BUSINESS WIRE)--ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its SORT-LNP™ platform for the treatment of life-limiting respiratory diseases, today announced that the Company will participate in two upcoming virtual investor conferences in June:

  • JMP Securities Life Sciences Conference
    Format:
    Presentation by David Lockhart, Ph.D., CEO and President; Julie Eastland, COO and CFO, will also participate in virtual 1x1 meetings
    Date: Wednesday, June 16, 2021
    Time: 4:00 – 4:25 p.m. ET

    The presentation will be webcast live and available for replay here.

  • LifeSci Partners Genetic Medicines Summit
    Format:
    Presentation and Q&A by David Lockhart, Ph.D., CEO and President
    Date: Tuesday, June 22, 2021
    Time: 1:00 – 1:25 p.m. ET

    An archived replay of the presentation will be made available on the Company’s website following the presentation.

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful, proprietary SORT-LNP™ platform to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its SORT-LNP™ and nucleic acid technologies, utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005259/en/

Contacts

Media Contact:
Will Zasadny
Canale Communications, Inc.
will.zasadny@canalecomm.com
(619) 961-8848

Investor Contact:
Sarah McCabe
Stern Investor Relations
sarah.mccabe@sternir.com
IR@recodetx.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting